

COMMENTARY ON:

PEEK-OPTIMA™ as an Alternative to Cobalt Chrome in the Femoral Component of Total Knee Replacement : A Preliminary Study

COMMENTARY AUTHOR: Adam Briscoe, PhD – InVibio Biomaterial Solutions

AUTHORS OF ORIGINAL PAPER: Raelene M Cowie PhD, Dr Adam Briscoe PhD, Prof Dr John Fisher PhD CEng FIMechE CSci FIPEM FREng CBE and Louise M Jennings PhD CEng FIMechE

JOURNAL: Proceedings of the Institution of Mechanical Engineers Part H: Journal of Engineering in Medicine, 2016 Nov; 230(11): 1008–1015. Published online 2016 Sep 16. doi: 10.1177/0954411916667410

LEVEL OF EVIDENCE: Peer Reviewed, Pre-clinical, *In-vitro* Study

Summary

In order to demonstrate the suitability of a bearing solution in total joint replacements, experimental wear simulation testing *in vitro* is considered the norm. ISO 14243 provides a gait profile for standard testing methodologies in the dynamic simulation of a knee prosthesis. It has recently been shown that this standard may not represent a worst case when analyzing these components. Several research groups have begun to examine how this standard can be improved upon. Previous work from the University of Leeds has shown that by increasing the anterior-posterior (AP) displacement during testing, some prostheses may also display a dramatic increase in the amount of observed wear.

This paper compares the wear performance of a total knee replacement (TKR) with a novel PEEK-OPTIMA polymer femoral component to that of an identical bearing design made from cobalt chrome (CoCr) alloy. Initial testing was carried out under standardized conditions (intermediate kinematics) and, after three million cycles, testing was continued under high kinematic conditions to a total of six million cycles.

The gravimetric results from this study showed that both CoCr (metallic) and PEEK-OPTIMA components produced statistically similar quantities of wear under both intermediate and high displacements. There was little change in the wear when changing the level of AP displacement. In all scenarios the amount of wear measured was low when compared to current alternative TKR designs. Figure 1 shows the comparison between the wear rate under intermediate kinematics for both CoCr and PEEK-OPTIMA femoral components and a comparison with a referenced data point of a current TKR femoral component brand, under the same conditions.¹




Fig. 1: Comparative volumetric wear rate between a CoCr knee, PEEK-OPTIMA knee and a current TKR femoral component brand.¹ Copyright ©2017 InVibio Ltd.

Key Findings

Based on this intermediate and high kinematic knee gait simulation wear test, there is no statistically significant difference in tibio-femoral wear produced between CoCr or PEEK-OPTIMA femoral components with the same bearing geometry.

Commentary

This paper provides a useful insight into the effects of a revolutionary change of biomaterial for one of the two most commonly replaced joints. A first look at the wear performance of a PEEK-OPTIMA polymer on Ultra-high-molecular-weight polyethylene (UHMWPE) TKR indicates that it can be potentially used as an alternative to CoCr alloy for the development of these types of devices.

Additional mechanical tests have now been performed to establish pre-clinical safety and suitability for the device to be used in a clinical setting. ▲

ABOUT THE AUTHOR**Adam Briscoe, PhD**

Dr Adam Briscoe is the Technology Manager for Orthopedics at Invibio Biomaterial Solutions. He has more than 15 years of experience working in research and development for orthopedic medical devices. In 2007, he received a PhD in biomechanical engineering from the University of Southampton, in the United Kingdom. Since April 2017, he has been a visiting research fellow at the University of Leeds, in the United Kingdom, focused on tribology research.

**REFERENCE**

1. A. L. Galvin, et al. Effect of conformity and contact stress on wear in fixed-bearing total knee prostheses. *J Biomech.* 2009 Aug 25;42(12):1898-902.

Copyright ©2017 Invibio Ltd. INVIBIO™, PEEK-OPTIMA™, INVIBIO BIOMATERIAL SOLUTIONS™ are trademarks of Victrex plc or its group companies. All rights reserved.



Invibio Ltd.

Victrex Technology Centre
Hillhouse International
Thornton-Cleveleys
Lancashire
FY5 4QD, UK

Tel: +44 (0) 1253 898 000

FAX: +44 (0) 1253 898 001

Invibio Inc.

300 Conshohocken State Road
West Conshohocken, PA
19428
USA

Toll Free: 866-INVIBIO (468-4246)

Tel: (484) 342-6004

Fax: (484) 342-6005

**For further information please email us at info@invibio.com
or visit our website at:**

► Invibio.com

Victrex plc and/or its group companies ("Victrex plc") believes that the information in this document is an accurate description of the typical characteristics and/or uses of the product or products, but it is the customer's responsibility to thoroughly test the product in each specific application to determine its performance, efficacy, and safety for each end-use product, device or other application. Suggestions of uses should not be taken as inducements to infringe any particular patent. The information and data contained herein are based on information we believe reliable. Mention of a product in this document is not a guarantee of availability.

Victrex plc reserves the right to modify products, specifications and/or packaging as part of a continuous program of product development. Victrex plc makes no warranties, express or implied, including, without limitation, a warranty of fitness for a particular purpose or of intellectual property non-infringement, including, but not limited to patent non-infringement, which are expressly disclaimed, whether express or implied, in fact or by law.

Further, Victrex plc makes no warranty to your customers or agents, and has not authorized anyone to make any representation or warranty other than as provided above. Victrex plc shall in no event be liable for any general, indirect, special, consequential, punitive, incidental or similar damages, including without limitation, damages for harm to business, lost profits or lost savings, even if Victrex has been advised of the possibility of such damages regardless of the form of action.

Supporting information is available on request for all claims referenced in this document.

Copyright ©2017 Invibio Ltd. INVIBIO™, JUVORA™ PEEK-OPTIMA™, INVIBIO BIOMATERIAL SOLUTIONS™ are trademarks of Victrex plc or its group companies. All rights reserved.